DSP Healthcare Fund Direct Growth

DSP Healthcare Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 05-12-2024

₹ 45.56

Inception Returns

28.7%

/yr

About DSP Healthcare Fund Direct Growth

DSP Healthcare Fund Direct Growth is an equity fund. This fund was started on 30 November, 2018. The fund is managed by Chirag Dagli. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. DSP Healthcare Fund Direct Growth has ₹3138 Cr worth of assets under management (AUM) as on Oct 2024 and is more than category average.
  2. The fund has an expense ratio 0.6.

Returns

DSP Healthcare Fund Direct Growth has given a CAGR return of 28.67% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 47.68%, 24.55% and 32.92% respectively.

Holdings

DSP Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Suven Pharmaceuticals Ltd, Ipca Laboratories Ltd, Cipla Ltd, Illumina Inc

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of DSP Healthcare Fund Direct Growth

The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. DSP Healthcare Fund Direct Growth has no lock in period.

Historical NAV & Returns

Annualised

zero opening, trading, fund transfer fee
6988 people have invested ₹ 4.8Cr in DSP Healthcare Fund Direct Growth in the last three months

INDmoney Rank for DSP Healthcare Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
5Y returns in the top 25% of the category
img
3Y returns in the top 25% of the category
img
Among most bought funds within the category
img
No bad points found for this fund.

DSP Healthcare Fund Direct Growth Overview

Expense ratio0.59%
Benchmark
S&P BSE Healthcare PR
AUM₹3138 Cr
Inception Date30 November, 2018
Min Lumpsum/SIP₹100/₹100
Exit Load
0.5%
Lock InNo Lock-in
TurnOver
17.89%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (05-Dec-24)

Period
DSP Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
0.8%
1.2%
0.6%
3M
3.8%
-0.7%
0.5%
6M
29.1%
9.1%
23%
1Y
47.7%
24.8%
43.1%
3Y
24.5%
16.8%
20.6%
5Y
32.9%
19.2%
27.8%

Fund Distribution

as on (31-Oct-24)

  • Equity 97.3%

  • Debt & Cash 2.7%

Small cap
40.3%

Large cap
22.1%

Mid cap
18.5%

Sector Allocation

Oct'24

Sep'24

Aug'24

Health
98.5%
Financial Services
1.5%
All changes are between Aug'24 and Oct'24
Oct'24
Sep'24
Aug'24
Fund Returns
-0.09%
3.75%
5.51%
Nifty 500
-6.52%
2.04%
0.97%
  • This fund’s returns stands at -0.09% whereas the fund’s underlying benchmark Nifty 500 returns stands at -6.52% as on Oct'24
  • This fund outperformed Nifty 500 by 6.43% in Oct'24
Parameters
Oct'24
Sep'24
Aug'24
AUM
₹ 3.1K Cr
₹ 3.1K Cr
₹ 2.9K Cr
  • AUM of the fund stands at 3.1K Cr as of Oct'24
  • AUM increased by 44.4 Cr between Oct'24 and Sep'24
Top Stocks bought last month
Gland Pharma Ltd's allocation increased from 2.07% to 4.33%
Gland Pharma Ltd's allocation increased from 2.07% to 4.33%
Suven Pharmaceuticals Ltd's allocation increased from 9.8% to 10.82%
Suven Pharmaceuticals Ltd's allocation increased from 9.8% to 10.82%
Emcure Pharmaceuticals Ltd's allocation increased from 0.77% to 1.57%
Emcure Pharmaceuticals Ltd's allocation increased from 0.77% to 1.57%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 11.68 % to 11.05 %
Sun Pharmaceuticals Industries Ltd's allocation decreased from 11.68 % to 11.05 %
Cipla Ltd's allocation decreased from 7.41 % to 6.85 %
Cipla Ltd's allocation decreased from 7.41 % to 6.85 %
Alembic Pharmaceuticals Ltd's allocation decreased from 5.55 % to 5.12 %
Alembic Pharmaceuticals Ltd's allocation decreased from 5.55 % to 5.12 %
Mid Cap allocation has gone down from 20% to 18.5%
Mid Cap allocation has gone down from 20% to 18.5%
Large Cap allocation has gone down from 23.4% to 22.1%
Large Cap allocation has gone down from 23.4% to 22.1%
Small Cap allocation has gone up from 38.2% to 40.3%
Small Cap allocation has gone up from 38.2% to 40.3%
Cash allocation has gone down from 3.3% to 2.7%
Cash allocation has gone down from 3.3% to 2.7%

Top 2 Sectors in October were Health, Financial Services

Oct'24
Health
98%
Financial Services
2%
Sep'24
Health
98%
Financial Services
2%
Fund
Oct'24
Sep'24
Aug'24
No of Holdings
32
31
31
Top 5 Company Concentration
42.2%
44.4%
45.5%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (11%)
Sun Pharmaceuticals Industries Ltd (11.7%)
Sun Pharmaceuticals Industries Ltd (11.6%)
No of Sectors
2
2
2
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (98.5%)
Health (98.2%)
Health (98.1%)
Loading...
We are taking more time than usual
Chirag Dagli
Chirag Dagli
Fund Manager of DSP Healthcare Fund Direct Growth, since 1 December 2020
Top funds managed
Fund House
DSP Asset Managers Private Limited
Total Schemes
Total AUM
₹1.28L Cr
as on 30-Sep-2023
Address
India
Phone
91-22-66578000
Website
service@dspblackrock.com

Mutual Fund Insights

Insights icon
Over the last 1 year, this fund has decreased expense ratio by 18.1% moving from 0.72 to 0.59.
Insights icon
Over the last 6 months, this fund has experienced a 33.9% growth in AUM moving from 2.34K Cr to 3.13K Cr.
Insights icon
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 53.89% return, outperforming this fund by 6.21%.
Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.59% which is lower than the category average expense ratio of 1.39%.
Insights icon
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 26.19% return, outperforming this fund by 1.64% per annum.
Insights icon
In the last 5 years, this fund has outperformed all funds in its category.

DSP Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 28.67% since inception which is more than its category average return of 26.52%
Fund Allocations

Fund Allocations

This fund has an allocation of 97.28% in Equity, 0% in Debt and 2.72% in Cash related instruments
AUM size ₹3138 Cr

AUM size ₹3138 Cr

This fund has AUM of ₹3138 Cr which is more than its category average of ₹ 1846 Cr
Expense Ratio 0.59%

Expense Ratio 0.59%

This fund has an expense ratio of 0.59% which is less than its category average expense ratio of 1.22%

Frequently Asked Questions for DSP Healthcare Fund Direct Growth

The current NAV of DSP Healthcare Fund Direct Growth is ₹45.56 as on 05-Dec-2024.
Existing (Absolute + CAGR) as on 05-Dec-2024.
DSP Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
0.82%
0.82%
6 Month Returns
29.1%
29.1%
1 Year Returns
47.68%
47.68%
3 Years Returns
93.21%
24.55%
5 Years Returns
314.87%
32.92%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.59% as on November 2024
₹3138 Cr as on November 2024
Sun Pharmaceuticals Industries Ltd(11.05%), Suven Pharmaceuticals Ltd(10.82%), Ipca Laboratories Ltd(8.12%), Cipla Ltd(6.85%), Illumina Inc(5.38%) as on November 2024
The alpha ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
DSP Healthcare Fund Direct Growth
4.3
3.77
8.13
As on November 2024
The alpha for DSP Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
DSP Healthcare Fund Direct Growth
0.94
0.92
0.8
As on November 2024
The Beta for DSP Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
DSP Healthcare Fund Direct Growth
2.6
1.08
1.47
As on November 2024
The sharpe ratio for DSP Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
DSP Healthcare Fund Direct Growth
13.01
15.54
16.97
As on November 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 2.07 as on November 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.67 as on November 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Chirag Dagli is the fund manager of DSP Healthcare Fund Direct Growth
The Exit load of DSP Healthcare Fund Direct Growth is 0.5%